These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 1446461)

  • 1. Drug therapy of hyperlipidemia.
    Prihoda JS; Illingworth DR
    Curr Probl Cardiol; 1992 Sep; 17(9):545-605. PubMed ID: 1446461
    [No Abstract]   [Full Text] [Related]  

  • 2. Hyperlipidemia: diagnostic and therapeutic perspectives.
    Ballantyne CM; Grundy SM; Oberman A; Kreisberg RA; Havel RJ; Frost PH; Haffner SM
    J Clin Endocrinol Metab; 2000 Jun; 85(6):2089-112. PubMed ID: 10852435
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of combined hyperlipidemia with fluvastatin and gemfibrozil, alone or in combination, does not induce muscle damage.
    Smit JW; Jansen GH; de Bruin TW; Erkelens DW
    Am J Cardiol; 1995 Jul; 76(2):126A-128A. PubMed ID: 7604787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining niacin with statins: does it help heart health?
    Johns Hopkins Med Lett Health After 50; 2011 Dec; 23(10):1-2. PubMed ID: 22216465
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of pravastatin with crystalline nicotinic acid monotherapy in treatment of combined hyperlipidemia.
    Mostaza JM; Schulz I; Vega GL; Grundy SM
    Am J Cardiol; 1997 May; 79(9):1298-301. PubMed ID: 9164913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of combination therapy for dyslipidemia: a lipid clinic approach.
    Brown AS
    Am J Cardiol; 2002 Nov; 90(10B):44K-49K. PubMed ID: 12467939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin-niacin combination therapy.
    Duvall WL; Blazing MA; Saxena S; Guyton JR
    J Cardiovasc Risk; 2002 Dec; 9(6):339-47. PubMed ID: 12478203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy for dyslipidemia: safety and regulatory considerations.
    Davidson MH
    Am J Cardiol; 2002 Nov; 90(10B):50K-60K. PubMed ID: 12467940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dietitian intervention improves lipid values and saves medication costs in men with combined hyperlipidemia and a history of niacin noncompliance.
    Sikand G; Kashyap ML; Wong ND; Hsu JC
    J Am Diet Assoc; 2000 Feb; 100(2):218-24. PubMed ID: 10670395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The rationale for combination therapy.
    Rosenson RS
    Am J Cardiol; 2002 Nov; 90(10B):2K-7K. PubMed ID: 12467935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia.
    Broyles FE; Walden CE; Hunninghake DB; Hill-Williams D; Knopp RH
    Am J Cardiol; 1995 Jul; 76(2):129A-135A. PubMed ID: 7604788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Drug therapy of dyslipidemias].
    Fonda M; Cattin L; Guarnieri G
    Recenti Prog Med; 2000; 91(7-8):375-8. PubMed ID: 10932924
    [No Abstract]   [Full Text] [Related]  

  • 13. Criteria for use of hypolipidemic agents in adults.
    Morales E; Spinler SA; Wilson MD; Chin MM; Jozefiak E
    Am J Hosp Pharm; 1994 Nov; 51(22):2837-41. PubMed ID: 7856612
    [No Abstract]   [Full Text] [Related]  

  • 14. Statin therapy with ezetimibe or niacin in high-risk patients.
    Kastelein JJ; Bots ML
    N Engl J Med; 2009 Nov; 361(22):2180-3. PubMed ID: 19915218
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy of fluvastatin, a totally synthetic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. FLUENT Study Group. Fluvastatin Long-Term Extension Trial.
    Zavoral JH; Haggerty BJ; Winick AG; Bergmann SD
    Am J Cardiol; 1995 Jul; 76(2):37A-40A. PubMed ID: 7604795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid disorders.
    Kole LA
    JAAPA; 2009 Nov; 22(11):54-5. PubMed ID: 19999177
    [No Abstract]   [Full Text] [Related]  

  • 17. Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol.
    Ballantyne CM; Shah S; Kher U; Hunter JA; Gill GG; Cressman MD; Ashraf TB; Johnson-Levonas AO; Mitchel YB
    Am J Cardiol; 2017 Feb; 119(3):388-396. PubMed ID: 27956003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapy and clinical trials: HDL-cholesterol and niacin therapy--past, present, and future.
    Virani SS; Ballantyne CM
    Curr Opin Lipidol; 2010 Apr; 21(2):165-6. PubMed ID: 20616632
    [No Abstract]   [Full Text] [Related]  

  • 19. [Non-alcoholic hepatic steatosis: the role of policosanols in associated hyperlipidemia].
    Musto D; Martorelli L; Russo M; Esposito G; Amato MR; Esposito P; Riegler G
    Minerva Gastroenterol Dietol; 2010 Dec; 56(4):389-95. PubMed ID: 21139538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of fluvastatin and pravastatin on lipid profiles and thromboxane production in type IIa hypercholesterolemia.
    Milani M; Cimminiello C; Merlo B; Lorena M; Arpaia G; Bonfardeci G
    Am J Cardiol; 1995 Jul; 76(2):51A-53A. PubMed ID: 7604798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.